UCART 123

Drug Profile

UCART 123

Alternative Names: Anti-CD123 CAR-T Cells-Cellectis

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellectis
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 04 Sep 2017 The US FDA places a clinical hold on studies of UCART 123 for Acute myeloid leukaemia and blastic plasmacytoid dendritic cell neoplasm, following a fatality
  • 04 Sep 2017 Adverse events data from two phase I trials in Acute myeloid leukaemia and blastic plasmacytoid dendritic cell neoplasm released by Cellectis
  • 17 Aug 2017 Cellectis initiates enrolment in a phase I trial for Haematological malignancies (Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top